Ablynx nv


Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 200 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Nanobodies® have been generated against more than 100 different disease targets. Efficacy data has been obtained in over 25 in vivo models for Nanobodies® against a range of different targets.

More about Ablynx
  • News

    Sanofi to acquire Ablynx

    Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, whic ... more

    ABLYNX appoints Markus Ewert as Chief Business Officer

    Ablynx announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company's business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for near ... more

    Ablynx to receive milestone for bi-specific nanobody in oncology

    Ablynx announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the s ... more